ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
트레프로스틴일 나트륨 시장 규모는 향후 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 9.5%를 나타내 18억 달러로 성장할 전망입니다. 예측 기간의 성장은 약물전달 기술의 진보, 병용 요법의 채용 증가, 임상시험 및 연구 활동에 대한 투자 증가, 노인 인구 증가, 헬스케어 지출 증가에 기인하고 있습니다. 예측 기간의 주요 동향으로는 개량형 분무기 및 건조 분말 흡입 제제의 개발, 서방형 제제의 진보, 병용 요법의 채용, 보다 안정적이고 생물학적 이용능이 높은 경구 제제의 개발, 새로운 치료 용도를 모색하는 임상시험의 진행 등을 들 수 있습니다.
향후 5년간의 성장률 9.5%라고 하는 예측은 이 시장에 관한 전회의 예측으로부터 0.4%의 소폭의 감소를 반영하고 있습니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향 때문입니다. 무역 제한으로 인해 영국과 이스라엘에서 수입되는 프로스타사이클린 유사 물질 및 지속 주입 요법의 비용이 증가하고 드문 심혈관 질환의 치료가 지연됨으로써 미국의 폐 고혈압 프로그램에 영향을 미칠 수 있습니다. 또한 상호관세와 무역의 긴장과 한계 증가로 인한 세계경제와 무역에 대한 악영향으로 인해 그 영향이 더욱 광범위해질 것으로 보입니다.
폐 질환의 이환율 증가는 향후 수년간 트레프로스틴일 나트륨 시장 확대를 이끌 것으로 예측됩니다. 폐 질환은 폐와 호흡기 시스템에 영향을 미치고 호흡과 산소 순환을 손상시킵니다. 대기 오염, 흡연, 환경 독소, 노화 등의 요인이 이러한 질병의 유병률 상승에 기여합니다. 혈관 확장제인 트레프로스틴일 나트륨은 폐 혈관을 이완시키고, 압력을 낮추고, 호흡을 개선하며, 폐 질환의 유연한 치료 옵션을 제공합니다. 예를 들어, 2024년 6월 호주 정부 기관인 호주 보건복지연구소(Australian Institute of Health and Welfare)의 자료에 따르면, 만성 폐쇄성 폐질환(COPD)으로 인한 사망자는 2022년 기준 7,691명으로 집계되었으며, 이는 인구 10만 명당 29.6명의 사망률을 나타내며 전체 사망자의 4.0%를 차지했습니다. 그 결과, 폐질환 환자 증가가 트레프로스틴일 나트륨 수요에 박차를 가하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁과 관세, 그리고 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 트레프로스틴일 나트륨 : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 성장 촉진요인과 억제요인)
최종 이용 산업의 분석
세계의 트레프로스틴일 나트륨 시장 : 성장률 분석
세계의 트레프로스틴일 나트륨 시장 실적 : 규모와 성장(2019-2024년)
세계의 트레프로스틴일 나트륨 시장 예측 : 규모와 성장(2024-2029년, 2034년)
세계의 트레프로스틴일 나트륨 : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 트레프로스틴일 나트륨 시장 : 제품 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
주사제
흡입제
경구제
세계의 트레프로스틴일 나트륨 시장 : 용도별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
폐동맥 고혈압
만성 혈전색전성 폐고혈압
기타 용도
세계의 트레프로스틴일 나트륨 시장 : 유통 채널별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
병원
전문 클리닉
온라인 약국
소매 약국
세계의 트레프로스틴일 나트륨 시장 : 주사제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
피하 주사
정맥 주입
세계의 트레프로스틴일 나트륨 시장 : 흡입제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
흡입 에어로졸
분무기 용액
세계의 트레프로스틴일 나트륨 시장 : 경구제 유형별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
서방형 정제
경구 현탁액
제7장 지역별/국가별 분석
세계의 트레프로스틴일 나트륨 시장 : 지역별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
세계의 트레프로스틴일 나트륨 시장 : 국가별, 분석과 예측(2019-2024년, 2024-2029년, 2034년)
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 프로파일
트레프로스틴일 나트륨 시장 : 경쟁 구도
트레프로스틴일 나트륨 시장 : 기업 프로파일
Eli Lilly and Company : 개요, 제품 및 서비스, 전략 및 재무 분석
Teva Pharmaceutical Industries Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Sandoz International GmbH : 개요, 제품 및 서비스, 전략 및 재무 분석
Dr. Reddy's Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
United Therapeutics Corporation : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Euroapi SA
Alembic Pharmaceuticals Ltd.
Cayman Chemical
Chirogate International
Farbe Firma Pvt Ltd.
Simson Pharma Limited
YONSUNG Fine Chemicals Co. Ltd.
Liquidia Corporation
ChemWerth Inc.
Mylan Laboratories Limited
Nuray Chemicals Private Limited
Endo International plc
LGM Pharma
Northern Therapeutics Inc
KPS Chemicals Pharmaceuticals
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장의 잠재력이 높은 국가, 부문, 전략
트레프로스틴일 나트륨 시장(2029년) : 새로운 기회를 제공하는 국가
트레프로스틴일 나트륨 시장(2029년) : 새로운 기회를 제공하는 부문
트레프로스틴일 나트륨 시장(2029년) : 성장 전략
시장 동향에 기초한 전략
경쟁 전략
제36장 부록
KTH
영문 목차
영문목차
Treprostinil sodium is a synthetic prostacyclin (PGI2) analogue used to treat pulmonary arterial hypertension (PAH) by improving exercise capacity and alleviating symptoms. It works by promoting vasodilation, inhibiting platelet aggregation, and reducing vascular remodeling, thereby lowering pulmonary pressure, enhancing blood flow, and slowing disease progression to improve the quality of life.
The main product types of treprostinil sodium include injectable, inhalable, and oral formulations. The injectable form is administered directly via syringe or needle to improve exercise capacity and reduce symptoms in PAH patients. Treprostinil sodium is used for various applications, including pulmonary arterial hypertension, chronic thromboembolic pulmonary hypertension, and other related conditions. It is distributed through multiple channels, such as hospitals, specialty clinics, online pharmacies, and retail pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment-many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.
The treprostinil sodium market research report is one of a series of new reports from The Business Research Company that provides treprostinil sodium market statistics, including the treprostinil sodium industry global market size, regional shares, competitors with the treprostinil sodium market share, detailed treprostinil sodium market segments, market trends, and opportunities, and any further data you may need to thrive in the treprostinil sodium industry. This treprostinil sodium market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The treprostinil sodium market size has grown strongly in recent years. It will grow from $1.15 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to rising demand for treprostinil sodium, increasing prevalence of pulmonary arterial hypertension (PAH), growing demand for treprostinil drugs, increasing awareness of the importance of respiratory health, and increasing investment in healthcare infrastructure.
The treprostinil sodium market size is expected to see strong growth in the next few years. It will grow to $1.8 billion in 2029 at a compound annual growth rate (CAGR) of 9.5%. The growth in the forecast period can be attributed to advancements in drug delivery technologies, rising adoption of combination therapies, increasing investment in clinical trials and research activities, a growing geriatric population, and rising healthcare expenditure. Major trends in the forecast period include the development of improved nebulized and dry powder inhaler formulations, advancements in sustained-release formulations, the adoption of combination therapies, the development of more stable and bioavailable oral formulations, and ongoing clinical trials exploring new therapeutic applications.
The forecast of 9.5% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade limitations could impact U.S. pulmonary hypertension programs by increasing costs of prostacyclin analogs and continuous infusion therapies imported from the UK and Israel, delaying treatment for rare cardiovascular conditions. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising incidence of pulmonary diseases is expected to drive the expansion of the treprostinil sodium market in the coming years. Pulmonary diseases affect the lungs and respiratory system, impairing breathing and oxygen circulation. Factors such as air pollution, smoking, environmental toxins, and an aging population contribute to the increasing prevalence of these conditions. Treprostinil sodium, a vasodilator, helps relax lung blood vessels, lower pressure, improve breathing, and provide flexible treatment options for pulmonary diseases. For example, in June 2024, data from the Australian Institute of Health and Welfare, an Australia-based government agency, revealed that chronic obstructive pulmonary disease (COPD) accounted for 7,691 deaths in 2022, translating to 29.6 deaths per 100,000 people and representing 4.0% of all fatalities. As a result, the growing number of pulmonary disease cases is fueling the demand for treprostinil sodium.
Leading companies in the treprostinil sodium market are prioritizing the development of advanced pulmonary arterial hypertension product formulations to enhance delivery methods. The formulation of pulmonary arterial hypertension (PAH) treatments involves designing medications with precise compositions to effectively manage PAH while reducing side effects. These formulations optimize the delivery of active ingredients for maximum therapeutic impact. For instance, in April 2023, Dr. Reddy's Laboratories, an India-based pharmaceutical firm, launched Treprostinil Injection in the U.S. market following approval by the Food and Drug Administration, a U.S.-based government agency. Treprostinil injection serves as a therapeutic equivalent generic version of Remodulin (treprostinil) injection, classified under prostacyclin mimetics, which are used to treat pulmonary arterial hypertension and alleviate exercise-related symptoms. It is available in vials containing 20 mg/20 mL, 50 mg/20 mL, 100 mg/20 mL, or 200 mg/20 mL.
In June 2023, Liquidia Corporation, a U.S.-based pharmaceutical company, collaborated with Pharmosa Biopharm to develop an inhaled, sustained-release formulation of treprostinil (L606) for pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). This partnership seeks to leverage Liquidia's expertise in pulmonary hypertension alongside Pharmosa's proficiency in inhaled liposomal formulations to revolutionize treatment options in regions where inhaled treprostinil formulations are not readily available. Pharmosa Biopharm is a China-based company specializing in liposomal formulations of treprostinil.
Major players in the treprostinil sodium market are Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Dr. Reddy's Laboratories, United Therapeutics Corporation, Euroapi SA, Alembic Pharmaceuticals Ltd., Cayman Chemical, Chirogate International, Farbe Firma Pvt Ltd., Simson Pharma Limited, YONSUNG Fine Chemicals Co. Ltd., Liquidia Corporation, ChemWerth Inc., Mylan Laboratories Limited, Nuray Chemicals Private Limited, Endo International plc, LGM Pharma, Northern Therapeutics Inc, KPS Chemicals Pharmaceuticals.
North America was the largest region in the treprostinil sodium market in 2024. The regions covered in treprostinil sodium report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the Treprostinil Sodium market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The treprostinil sodium market consists of sales of nasal spray formulation, buccal or lingual tablet, and nebulized solution. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Treprostinil Sodium Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on treprostinil sodium market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for treprostinil sodium ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The treprostinil sodium market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Product Type: Injectable; Inhalable; Oral
2) By Applications: Pulmonary Arterial Hypertension; Chronic Thromboembolic Pulmonary Hypertension; Other Applications
3) By Distribution Channel: Hospitals; Specialty Clinics; Online Pharmacies; Retail Pharmacies
Subsegments:
1) By Injectable: Subcutaneous Injection; Intravenous Infusion
2) By Inhalable: Inhalation Aerosol; Nebulizer Solution
3) By Oral: Extended-Release Tablets; Oral Suspension
Companies Mentioned: Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Sandoz International GmbH; Dr. Reddy's Laboratories; United Therapeutics Corporation; Euroapi SA; Alembic Pharmaceuticals Ltd.; Cayman Chemical; Chirogate International; Farbe Firma Pvt Ltd.; Simson Pharma Limited; YONSUNG Fine Chemicals Co. Ltd.; Liquidia Corporation; ChemWerth Inc.; Mylan Laboratories Limited; Nuray Chemicals Private Limited; Endo International plc; LGM Pharma; Northern Therapeutics Inc; KPS Chemicals Pharmaceuticals
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Treprostinil Sodium Market Characteristics
3. Treprostinil Sodium Market Trends And Strategies
4. Treprostinil Sodium Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Treprostinil Sodium Growth Analysis And Strategic Analysis Framework
5.1. Global Treprostinil Sodium PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Treprostinil Sodium Market Growth Rate Analysis
5.4. Global Treprostinil Sodium Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Treprostinil Sodium Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Treprostinil Sodium Total Addressable Market (TAM)
6. Treprostinil Sodium Market Segmentation
6.1. Global Treprostinil Sodium Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Injectable
Inhalable
Oral
6.2. Global Treprostinil Sodium Market, Segmentation By Applications, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Pulmonary Arterial Hypertension
Chronic Thromboembolic Pulmonary Hypertension
Other Applications
6.3. Global Treprostinil Sodium Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Online Pharmacies
Retail Pharmacies
6.4. Global Treprostinil Sodium Market, Sub-Segmentation Of Injectable, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Subcutaneous Injection
Intravenous Infusion
6.5. Global Treprostinil Sodium Market, Sub-Segmentation Of Inhalable, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Inhalation Aerosol
Nebulizer Solution
6.6. Global Treprostinil Sodium Market, Sub-Segmentation Of Oral, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Extended-Release Tablets
Oral Suspension
7. Treprostinil Sodium Market Regional And Country Analysis
7.1. Global Treprostinil Sodium Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Treprostinil Sodium Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
